- Home
- PCSC vs CUE Comparison
PCSC vs CUE Comparison
Compare PCSC & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSC
- CUE
- Stock Information
- Founded
- PCSC 2024
- CUE 2014
- Country
- PCSC United States
- CUE United States
- Employees
- PCSC N/A
- CUE N/A
- Industry
- PCSC
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- PCSC
- CUE Health Care
- Exchange
- PCSC NYSE
- CUE Nasdaq
- Market Cap
- PCSC 112.1M
- CUE 94.4M
- IPO Year
- PCSC 2024
- CUE 2018
- Fundamental
- Price
- PCSC $10.30
- CUE $1.32
- Analyst Decision
- PCSC
- CUE Strong Buy
- Analyst Count
- PCSC 0
- CUE 5
- Target Price
- PCSC N/A
- CUE $5.00
- AVG Volume (30 Days)
- PCSC 910.0
- CUE 195.8K
- Earning Date
- PCSC 01-01-0001
- CUE 03-10-2025
- Dividend Yield
- PCSC N/A
- CUE N/A
- EPS Growth
- PCSC N/A
- CUE N/A
- EPS
- PCSC N/A
- CUE N/A
- Revenue
- PCSC N/A
- CUE $9,532,000.00
- Revenue This Year
- PCSC N/A
- CUE $73.11
- Revenue Next Year
- PCSC N/A
- CUE $11.02
- P/E Ratio
- PCSC N/A
- CUE N/A
- Revenue Growth
- PCSC N/A
- CUE 149.53
- 52 Week Low
- PCSC $10.02
- CUE $0.45
- 52 Week High
- PCSC $10.30
- CUE $2.37
- Technical
- Relative Strength Index (RSI)
- PCSC N/A
- CUE 48.32
- Support Level
- PCSC N/A
- CUE $1.22
- Resistance Level
- PCSC N/A
- CUE $1.54
- Average True Range (ATR)
- PCSC 0.00
- CUE 0.11
- MACD
- PCSC 0.00
- CUE -0.01
- Stochastic Oscillator
- PCSC 0.00
- CUE 35.29
About PCSC PERCEPTIVE CAP SOLUTIONS CORP
Perceptive Capital Solutions Corp is a blank check company.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.